CHEMOTHERAPY: One Carrier Pushes Defunct Code For Zevalin, Bexxar

Why This Topic Matters

It highlights how draft coverage policies can differ from other payer instructions and how that can affect reporting for radiopharmaceutical localization, diagnostic imaging, and therapy-related services. Readers following payer policy changes will want to compare carrier guidance, Medicare updates, and the codes referenced in the article.

Article Sections

1. Draft local coverage guidance and radiopharmaceutical diagnostic coding

   Discusses a draft carrier policy and the broader issue of how radiopharmaceutical diagnostic services are being referenced in payer guidance. The section focuses on coverage interpretation and coding updates at a high level.

2. Carrier coverage policies and related coding guidance

   Summarizes how multiple carriers and policy sources address diagnostic and therapeutic services for monoclonal antibody radiopharmaceuticals. The section also notes that different payers may point to different billing approaches.

3. Commentary on draft policy status

   Provides a brief expert perspective on draft policy language and the importance of awaiting final guidance. It emphasizes the provisional nature of the referenced local coverage decision.